Gastroesophageal Reflux Disease (GERD) Market Size & Share, by Drug Type (Antacids, Proton Pump Inhibitors, H2 Receptor Blocker, Pro Kinetic Agents, Dopamine Receptor Antagonist, EndoCinch, Stretta, EsophyX, Transoral Incisionless, Fundoplication); Route of Administration (Oral, Parental); Distribution Channel (Hospital, Online, Retail); End-user (Hospital, Homecare, Specialty Clinics) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

Growth Drivers

• Growing Cases of Esophageal Diseases – Esophageal diseases are a group of diseases that affects the esophagus, the tube responsible for carrying food from the mouth to the stomach. It causes heat burn during eating and swallowing problems and increases the chances of GERD in a human being.
• Surge in Digestive Disorders – Regular drinking habits, lower physical exercise, and rising stress levels among the global population have led to an increase in digestive health disorders. This factor is estimated to fuel the global gastroesophageal reflux disease market size in the future. A report from 2022 stated that nearly 40% of Americans’ daily lives are disrupted by digestive troubles.
• High Prevalence of Gastrointestinal (GI) Tract Diseases – Owing to the consumption of an unhealthy amount of junk along with the rising stress, anxiety, and panic levels among the middle age population is anticipated to bring lucrative growth opportunities for market growth in the next few years. It is observed that in the United States, irritable bowel syndrome is common with a prevalence of about 12% to 14%.
• Increasing Desire for Eating Unhealthy Food Items – Fast-paced lives have propelled the working population for processed and junk food items owing to their easy availability, convenience, and taste. However, the outcome of eating unhealthy food daily is the development of gastroesophageal reflux disease (GERD). The consumption of ultra-processed food in the United States region has increased from around 54% in 2002 to approximately 57% in 2018.

Challenges

• High Cost of the Treatment – GERD is classified as a chronic disease that requires long-term disease management which is costly. Pharmaceutical costs along with the physician and hospital fees, medicine prices, and surgery charges are directly linked with the treatment of gastroesophageal disease. This is estimated to hamper market growth during the forecast period.
• Lack of Awareness Regarding the Disease
• Unavailability of Qualified Professionals and Supporting Staff